Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CBIO-007
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBIO-007, conditionally armed CAR-T cell therapy as potential treatment for tumors, was generated from Chimera’s proprietary GOLD Platform™ technology, which creates conditional, location-specific activation of tumor microenvironment -modifying paylo...
Product Name : CBIO-007
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 28, 2022
Lead Product(s) : CBIO-007
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable